

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 June 2023 (22.06.2023)



(10) International Publication Number
WO 2023/111112 A1

(51) International Patent Classification:

A61K 38/22 (2006.01) *A61P 11/00* (2006.01)
A61K 47/68 (2017.01) *C07K 14/64* (2006.01)
A61P 9/04 (2006.01)

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/086001

(22) International Filing Date:

14 December 2022 (14.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/289,687 15 December 2021 (15.12.2021) US
63/386,812 09 December 2022 (09.12.2022) US

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0AA (GB).

(72) Inventors: **GEORGE JR, Richard Thomas**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **CONNOLLY, Kathleen Marie**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0AA (GB). **OMAR, Sami Ali Abdel Hafees**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0AA (GB). **GABRIELSEN, Anders**; AstraZeneca AB, 151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Eastbrook House, Shaftesbury Road, Cambridge, Cambridgeshire CB2 8BF (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: TREATMENT USING HETERODIMERIC RELAXIN FUSIONS

(57) Abstract: The present invention relates to uses of heterodimeric Relaxin fusion polypeptides, in particular for the treatment of heart failure with pulmonary hypertension.

WO 2023/111112 A1